Characterization of missense mutations in the NADPH oxidase partner p22phox in the A22° subtype of chronic granulomatous disease

Microbiol Immunol. 2023 Apr;67(4):194-200. doi: 10.1111/1348-0421.13051. Epub 2023 Jan 22.


Defective superoxide production by NADPH oxidase 2 (Nox2) in phagocyte cells results in the development of chronic granulomatous disease (CGD), a hereditary disease characterized by recurrent and life-threatening infections. The partner protein p22phox is a membrane-spanning protein which forms a stable heterodimer with Nox2 in the endoplasmic reticulum. This interaction ensures the stability of each protein and their accurate trafficking to the cell membrane. The present paper describes the characterization of p22phox missense mutations that were identified in a patient with CGD who presented with undetectable levels of p22phox . Using a reconstitution system, it was found that p22phox expression decreased when R90Q, A117E, S118R, A124S, A124V, A125T, or E129K mutations were introduced, suggesting that these mutations destabilize the protein. In contrast, introducing an L105R mutation did not affect protein expression, but did inhibit p22phox binding to Nox2. Thus, the missense mutations discussed here contribute to the development of CGD by either disrupting protein stability or by impairing the interaction between p22phox and Nox2.

Keywords: NADPH oxidase; Nox2; chronic granulomatous disease; membrane protein; p22phox.

MeSH terms

  • Animals
  • Cell Line
  • Cricetulus
  • Humans
  • Mutation, Missense
  • NADPH Oxidase 2 / metabolism
  • NADPH Oxidases* / chemistry
  • NADPH Oxidases* / genetics
  • NADPH Oxidases* / metabolism


  • CYBA protein, human
  • NADPH Oxidases
  • CYBB protein, human
  • NADPH Oxidase 2